Heron Q4 net income $3.6M; FY2024 rev $144.2M (+14%); guides 2025 rev $153-163M

HERON THERAPEUTICS, INC. /DE/

2024-FY EPS reported -$0.09 revenue$144,285,000

Q4 2024 GAAP net income of $3.6M; full-year 2024 adjusted EBITDA of $8.6M.
Full-year 2024 net revenue $144.2M (+14% YoY); Acute Care revenue up 57%, Oncology up 6%.
2025 guidance: net revenue $153-163M, adjusted EBITDA $0-8M.
U.S. District Court upheld CINVANTI patents against Fresenius Kabi; patents expire 2035.
Cash and investments $59.3M; ZYNRELEF VAN launched Dec 2024; Crosslink partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.